Unlock instant, AI-driven research and patent intelligence for your innovation.

A kind of autologous hematopoietic stem cell modified by hbb fusion gene, preparation method and application thereof

A technology of hematopoietic stem cells and fusion genes, applied to genetically modified cells, cells modified by introducing foreign genetic material, botanical equipment and methods, etc., can solve the problems of lack of hypersensitive sites and low expression of hemoglobin

Active Publication Date: 2022-07-12
SHANDONG XINRUI BIOTECH CO LTD
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] CN110582305A is an invention patent of American Bluebird Biological Company, which mainly provides a gene therapy vector expressing normal hemoglobin, which lacks HS4 DNase I hypersensitive site, and the expression level of hemoglobin is low
However, the nucleotide point mutation or deletion in the HBB gene in this patent is selected from other mutations such as the deletion of C at position 264 or 265, and the expression of hemoglobin is low

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A kind of autologous hematopoietic stem cell modified by hbb fusion gene, preparation method and application thereof
  • A kind of autologous hematopoietic stem cell modified by hbb fusion gene, preparation method and application thereof
  • A kind of autologous hematopoietic stem cell modified by hbb fusion gene, preparation method and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0032] Example 1 Construction of recombinant expression vector pCDH-HBB

[0033] Comments on HBB fusion gene module figure 1 (See Appendix SEQ ID NO. 1 for the complete nucleic acid sequence).

[0034] The sequence of each module of HBB fusion gene

[0035] (1) DNase I hypersensitive site HS2 (SEQ ID NO.2)

[0036] (2) DNase I hypersensitive site HS3 (SEQ ID NO.3)

[0037] (3) DNase I hypersensitive site HS4 (SEQ ID NO.4)

[0038] (4) Promoter (SEQ ID NO.5)

[0039] (5) Enhancer (SEQ ID NO.6)

[0040] (6) HSb T87Q (SEQ ID NO.7)

[0041] Above-mentioned DNase I hypersensitive sites HS2-HS4 are core sequences cut from full-length sequences;

[0042] The present application has carried out codon optimization on the nucleotide sequence of HSb T87Q;

[0043] According to the above SEQ ID NO.1 sequence, Shanghai Jierui Bioengineering Co., Ltd. was entrusted to synthesize its entire expression cassette, inserted into the pCDH vector (provided by the Chinese Center for Disease...

Embodiment 2

[0046] Example 2 Packaging and titer determination of lentivirus

[0047] 1) Recovery of packaging cell lines

[0048] The packaging cell line used in the present invention is 293T cells. Take out the cryopreserved 293T cells from the liquid nitrogen tank, quickly throw them into a 37°C water bath and shake quickly, and try to dissolve the cell solution completely within 2 min. Transfer 1 mL of cell solution to a 50 mL centrifuge tube, add 35 mL of normal saline to wash DMSO, mix well and centrifuge under the following conditions: 1500 rpm, 5 min. Remove the supernatant, add 5 mL of fresh high-glucose DMEM (containing 10 Vol% FBS) medium to resuspend the cells, and transfer them to T75 flasks. Continue adding high-glucose DMEM (containing 10 Vol% FBS) medium to each flask. volume to 10mL. Put the culture flask steadily at 37°C, 5% CO2 cultured in an incubator. Cell viability was observed the next day, and the medium was changed. The cell growth was observed every day ther...

Embodiment 3

[0055] Example 3 Modification of CD34 by recombinant lentivirus + Preparation of cells

[0056] 1. CD34 + Cell sorting and culture

[0057] Before single-cell collection, patients took the drug Filgrastim, which stimulates the production of cells in the body, and single cells were collected on day 5. The collected cells were sorted by magnetic beads using the CD34 MicroBead Kit provided by Miltenyi to sort CD34 + cells, for cell counting, the concentration was 5 x 10 5 cells / mL of cell culture medium were inoculated into six-well plates, supplemented with 2 mL of CD34 expansion medium in each well, and placed at 37°C in 5% CO. 2 Incubator for 2 days. Six-well plate pre-used with 5µg / cm 2 The Fibronectin (purchased from Gibco) was placed in a 37°C incubator for 6 h, and the CD34 expansion medium was StemSpan SFEMMedium (purchased from STEMCELL Technologies), containing 20ng / mL SCF, 200ng / mL Flt-3L and 100ng / mL TPO ( were purchased from MCE Corporation).

[0058] 2. Infe...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides an autologous hematopoietic stem cell modified by HBB fusion gene, a preparation method and application thereof, and belongs to the technical field of genetic engineering. The HBB fusion gene is obtained by connecting the following modules in sequence: DNase I hypersensitive site HS2, DNase I hypersensitive site Site HS3, DNase I hypersensitive site HS4, promoter, enhancer, HSb T87Q; the nucleotide sequence of the HBB fusion gene is shown in SEQ ID NO.1 of the sequence table. The present invention utilizes nucleotide-optimized HBB fusion gene-modified CD34 + cells that secreted a higher amount of human haptoglobin and a higher number of erythroid colonies.

Description

technical field [0001] The present application relates to an autologous hematopoietic stem cell modified by HBB fusion gene, a preparation method and application thereof, and belongs to the technical field of genetic engineering. Background technique [0002] Sickle cell disease (SCD) and beta-thalassemia (beta-TM) are the most common monogenic disorders in the world, affecting approximately 400,000 pregnant women or newborns each year. These diseases are mutations in two distinct types of beta-globin genes, resulting in either abnormal hemoglobin structure (SCD) or substantial reduction or deletion of beta-globin chains (beta-TM). The clinical manifestations of such genetic disorders typically appear in the first few months of life, when gene expression switches from fetal γ-globin chains to the formation of adult βA-globin chains (HbA). [0003] Allogeneic hematopoietic stem cell transplantation (AHSCT) is currently recommended as a treatment option for β-TM if a human le...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C12N5/10C12N5/0789C12N15/867C12N15/62
CPCC12N5/0647C12N15/86C07K14/805C12N2740/15043C12N2510/02C07K2319/00
Inventor 刘明录张传鹏韩庆梅强邦明王立新冯建海金海锋许淼
Owner SHANDONG XINRUI BIOTECH CO LTD